Walvax COVID-19 vaccine (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Walvax COVID-19 vaccine" in English language version.

refsWebsite

Global rank English rank

12nih.gov

4^th place

6doi.org

2^nd place

5reuters.com

49^th place

47^th place

4scmp.com

362^nd place

245^th place

2chictr.org.cn

low place

2web.archive.org

1^st place

1wipo.int

1,462^nd place

1,223^rd place

1drugbank.com

low place

1informa.com

low place

1clinicaltrials.gov

5,225^th place

4,062^nd place

1nst.com.my

1,512^th place

1,019^th place

chictr.org.cn

"A Phase I clinical trial to evaluate the safety, tolerance and preliminary immunogenicity of different doses of a SARS-CoV-2 mRNA vaccine in population aged 18–59 years and 60 years and above". Chinese Clinical Trial Register. 24 June 2020. ChiCTR2000034112. Archived from the original on 11 October 2020. Retrieved 6 July 2020.
"A Phase II clinical trial to evaluate the immunogenicity and safety of different doses of a novel coronavirus pneumonia (COVID-19) mRNA vaccine in population aged 18-59 years". chictr.org.cn. Chinese Clinical Trial Registry. Archived from the original on 16 March 2021. Retrieved 20 March 2020.

clinicaltrials.gov

Clinical trial number NCT04847102 for "A Global, Multi-center, Randomized, Double-blind, Placebo-controlled, Phase III Clinical Trial to Evaluate the Protective Efficacy, Safety, and Immunogenicity of a SARS-CoV-2 Messenger Ribonucleic Acid (mRNA) Vaccine Candidate in Population Aged 18 Years and Above" at ClinicalTrials.gov

doi.org

Liu X, Li Y, Wang Z, Cao S, Huang W, Yuan L, et al. (August 2022). "Safety and superior immunogenicity of heterologous boosting with an RBD-based SARS-CoV-2 mRNA vaccine in Chinese adults". Cell Research. 32 (8): 777–780. doi:10.1038/s41422-022-00681-3. PMC 9197092. PMID 35701541.
Chen GL, Li XF, Dai XH, Li N, Cheng ML, Huang Z, et al. (March 2022). "Safety and immunogenicity of the SARS-CoV-2 ARCoV mRNA vaccine in Chinese adults: a randomised, double-blind, placebo-controlled, phase 1 trial". The Lancet. Microbe. 3 (3): e193 – e202. doi:10.1016/S2666-5247(21)00280-9. PMC 8786321. PMID 35098177.
Zhang NN, Li XF, Deng YQ, Zhao H, Huang YJ, Yang G, et al. (September 2020). "A Thermostable mRNA Vaccine against COVID-19". Cell. 182 (5): 1271–1283.e16. doi:10.1016/j.cell.2020.07.024. PMC 7377714. PMID 32795413.
Chen GL, Li XF, Dai XH, Li N, Cheng ML, Huang Z, et al. (March 2022). "Safety and immunogenicity of the SARS-CoV-2 ARCoV mRNA vaccine in Chinese adults: a randomised, double-blind, placebo-controlled, phase 1 trial". The Lancet. Microbe. 3 (3): e193 – e202. doi:10.1016/S2666-5247(21)00280-9. PMC 8786321. PMID 35098177.
Deng Z, Zhang M, Zhu T, Zhili N, Liu Z, Xiang R, et al. (September 2020). "Dynamic changes in peripheral blood lymphocyte subsets in adult patients with COVID-19". International Journal of Infectious Diseases. 98: 353–358. doi:10.1016/j.ijid.2020.07.003. PMC 7334931. PMID 32634585.
Zhang HJ, Qi GQ, Gu X, Zhang XY, Fang YF, Jiang H, Zhao YJ (July 2021). "Lymphocyte blood levels that remain low can predict the death of patients with COVID-19". Medicine. 100 (28): e26503. doi:10.1097/MD.0000000000026503. PMC 8284734. PMID 34260527.

drugbank.com

go.drugbank.com

"SARS-CoV-2 mRNA vaccine". go.drugbank.com. Retrieved 10 April 2021.

informa.com

scrip.pharmaintelligence.informa.com

Yang B (14 May 2021). "How A Small Chinese Biotech Is Taking On mRNA Vaccine Giants". Scrip.

nih.gov

ncbi.nlm.nih.gov

Liu X, Li Y, Wang Z, Cao S, Huang W, Yuan L, et al. (August 2022). "Safety and superior immunogenicity of heterologous boosting with an RBD-based SARS-CoV-2 mRNA vaccine in Chinese adults". Cell Research. 32 (8): 777–780. doi:10.1038/s41422-022-00681-3. PMC 9197092. PMID 35701541.
Chen GL, Li XF, Dai XH, Li N, Cheng ML, Huang Z, et al. (March 2022). "Safety and immunogenicity of the SARS-CoV-2 ARCoV mRNA vaccine in Chinese adults: a randomised, double-blind, placebo-controlled, phase 1 trial". The Lancet. Microbe. 3 (3): e193 – e202. doi:10.1016/S2666-5247(21)00280-9. PMC 8786321. PMID 35098177.
Zhang NN, Li XF, Deng YQ, Zhao H, Huang YJ, Yang G, et al. (September 2020). "A Thermostable mRNA Vaccine against COVID-19". Cell. 182 (5): 1271–1283.e16. doi:10.1016/j.cell.2020.07.024. PMC 7377714. PMID 32795413.
Chen GL, Li XF, Dai XH, Li N, Cheng ML, Huang Z, et al. (March 2022). "Safety and immunogenicity of the SARS-CoV-2 ARCoV mRNA vaccine in Chinese adults: a randomised, double-blind, placebo-controlled, phase 1 trial". The Lancet. Microbe. 3 (3): e193 – e202. doi:10.1016/S2666-5247(21)00280-9. PMC 8786321. PMID 35098177.
Deng Z, Zhang M, Zhu T, Zhili N, Liu Z, Xiang R, et al. (September 2020). "Dynamic changes in peripheral blood lymphocyte subsets in adult patients with COVID-19". International Journal of Infectious Diseases. 98: 353–358. doi:10.1016/j.ijid.2020.07.003. PMC 7334931. PMID 32634585.
Zhang HJ, Qi GQ, Gu X, Zhang XY, Fang YF, Jiang H, Zhao YJ (July 2021). "Lymphocyte blood levels that remain low can predict the death of patients with COVID-19". Medicine. 100 (28): e26503. doi:10.1097/MD.0000000000026503. PMC 8284734. PMID 34260527.

pubmed.ncbi.nlm.nih.gov

Liu X, Li Y, Wang Z, Cao S, Huang W, Yuan L, et al. (August 2022). "Safety and superior immunogenicity of heterologous boosting with an RBD-based SARS-CoV-2 mRNA vaccine in Chinese adults". Cell Research. 32 (8): 777–780. doi:10.1038/s41422-022-00681-3. PMC 9197092. PMID 35701541.
Chen GL, Li XF, Dai XH, Li N, Cheng ML, Huang Z, et al. (March 2022). "Safety and immunogenicity of the SARS-CoV-2 ARCoV mRNA vaccine in Chinese adults: a randomised, double-blind, placebo-controlled, phase 1 trial". The Lancet. Microbe. 3 (3): e193 – e202. doi:10.1016/S2666-5247(21)00280-9. PMC 8786321. PMID 35098177.
Zhang NN, Li XF, Deng YQ, Zhao H, Huang YJ, Yang G, et al. (September 2020). "A Thermostable mRNA Vaccine against COVID-19". Cell. 182 (5): 1271–1283.e16. doi:10.1016/j.cell.2020.07.024. PMC 7377714. PMID 32795413.
Chen GL, Li XF, Dai XH, Li N, Cheng ML, Huang Z, et al. (March 2022). "Safety and immunogenicity of the SARS-CoV-2 ARCoV mRNA vaccine in Chinese adults: a randomised, double-blind, placebo-controlled, phase 1 trial". The Lancet. Microbe. 3 (3): e193 – e202. doi:10.1016/S2666-5247(21)00280-9. PMC 8786321. PMID 35098177.
Deng Z, Zhang M, Zhu T, Zhili N, Liu Z, Xiang R, et al. (September 2020). "Dynamic changes in peripheral blood lymphocyte subsets in adult patients with COVID-19". International Journal of Infectious Diseases. 98: 353–358. doi:10.1016/j.ijid.2020.07.003. PMC 7334931. PMID 32634585.
Zhang HJ, Qi GQ, Gu X, Zhang XY, Fang YF, Jiang H, Zhao YJ (July 2021). "Lymphocyte blood levels that remain low can predict the death of patients with COVID-19". Medicine. 100 (28): e26503. doi:10.1097/MD.0000000000026503. PMC 8284734. PMID 34260527.

nst.com.my

Daim N, Yunus A (27 July 2021). "Dr Adham: Covid-19 vaccine development in recruitment phase". New Straits Times. Retrieved 28 July 2021.

reuters.com

"Mexico to start late-stage clinical trial for China's mRNA COVID-19 vaccine". Reuters. 11 May 2021. Retrieved 14 May 2021.
"Nepal approves late-stage trials for Chinese mRNA vaccine candidate". Reuters. 27 August 2021. Retrieved 28 August 2021.
Widianto S, Liu R (30 September 2022). "A Chinese mRNA COVID vaccine is approved for the first time - in Indonesia". Reuters. Retrieved 18 November 2022.
Liu R (21 December 2020). "China starts work on plant for mRNA-based COVID-19 vaccine candidate - media". Reuters. Retrieved 10 April 2021.
Daniel FJ (12 August 2020). "Mexico to trial China, U.S. COVID-19 vaccines, may produce some". Reuters. Retrieved 10 April 2021.

scmp.com

Ma J (22 July 2021). "Domestic clinical trials planned for China's mRNA Covid-19 vaccine". South China Morning Post. Retrieved 23 July 2021.
Pinghui Z (1 September 2021). "Indonesia, Mexico approve phase 3 trials of Chinese mRNA vaccine hopeful". South China Morning Post. Retrieved 1 September 2021.
Pinghui Z (13 April 2021). "China's first mRNA vaccine ready for final stage trials". South China Morning Post. Retrieved 13 April 2021.
Pinghui Z (12 May 2021). "Late-stage trial of Chinese mRNA Covid-19 vaccine to begin in Mexico". South China Morning Post. Retrieved 17 May 2021.

web.archive.org

"A Phase I clinical trial to evaluate the safety, tolerance and preliminary immunogenicity of different doses of a SARS-CoV-2 mRNA vaccine in population aged 18–59 years and 60 years and above". Chinese Clinical Trial Register. 24 June 2020. ChiCTR2000034112. Archived from the original on 11 October 2020. Retrieved 6 July 2020.
"A Phase II clinical trial to evaluate the immunogenicity and safety of different doses of a novel coronavirus pneumonia (COVID-19) mRNA vaccine in population aged 18-59 years". chictr.org.cn. Chinese Clinical Trial Registry. Archived from the original on 16 March 2021. Retrieved 20 March 2020.

wipo.int

"Patent Landscape Report COVID-19-related vaccines and therapeutics" (PDF).